The US Supreme Court unanimously ruled in favor of Hikma Pharmaceuticals, ending a patent infringement lawsuit filed by Amarin. The dispute involved Hikma's generic icosapent ethyl, a fish oil-based medicine for severe hypertriglyceridemia, which Hikma launched with FDA approval in 2020 using a 'skinny label' to cover only non-patented uses. This ruling supports the legal framework for generic medicines, allowing Hikma to continue providing affordable generics to millions of American patients. The decision is expected to encourage generic competition and benefit healthcare access in the US.
Broadcom's stock fell 12.59% after its AI revenue guidance met but did not exceed high market expectations. Historically, similar steep drops in Broadcom shares have marked strong buying opportunities, with average gains over 85% in six months follow...
Rubrik reported Q1 earnings of 16 cents per share, beating the expected loss of three cents, with revenue of $387.07 million surpassing estimates. Subscription annual recurring revenue (ARR) grew 32% year-over-year to $1.57 billion. The company raise...
Diana Shipping Inc. has criticized Genco Shipping & Trading for changing its valuation methods to avoid engaging with Diana's $24.80 per share all-cash takeover offer. Diana argues it has consistently offered around 1.0x NAV based on broker valuation...
The HON Company has launched a new 12,000-square-foot flagship showroom in Chicago, designed as an immersive workplace and learning environment. The showroom integrates HON's portfolio across four zones—The Commons, The Sandbox, The Hub, and The Educ...
Medtronic reported adjusted earnings of $1.55 per share, slightly above estimates, and revenue rose 9.9% year-over-year to $9.81 billion, driven by strong cardiovascular segment growth. BTIG upgraded Medtronic from Neutral to Buy, citing accelerating...
